Short Summary
Dyson and Omachron have settled their dispute over U.S. Patent 11,903,546 and jointly moved to terminate the inter partes review. The motion cites statutory authority and prior Board guidance to support termination.
Detailed Summary
In IPR2024‑01162, Dyson Technology Limited and Dyson, Inc. jointly filed a motion to terminate the inter partes review of U.S. Patent No. 11,903,546, owned by Omachron Intellectual Property Inc. The parties have reached a settlement covering all disputes related to the patent. Relying on 35 U.S.C. §317(a) and Board policy favoring settlement, they argue that the statutory conditions for termination are satisfied and that a prior denial in a similar case has been resolved after the required waiting period. The motion includes an extensive exhibit list of prior‑art references and seeks to keep the settlement agreement confidential.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Dyson Technology Limited et al. vs Omachron Intellectual Property Inc. et al. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Alliance Laundry Systems, LLCvsPayRange LLC.
The PTAB granted institution for Post-Grant Review on all 20 claims of the '920 patent covering mobile payment systems, facing challenges under § 101 (eligibility) and § 103 (obviousness). The Board found sufficient evidence to proceed with arguments regarding abstract ideas and inventive concepts.
Mercedes-Benz Group AG et al.vsPhelan Group, LLC
Mercedes‑Benz has filed an IPR petition challenging all 20 claims of the Phelan Group’s driver‑authentication patent, asserting anticipation and obviousness over Murphy, Arshad, Adams, Wu and Petrik references.
Terumo BCT, Inc.vsHaemonetics Corporation
Haemonetics Corp. seeks Director review to vacate the institution of an IPR filed by Terumo BCT over its plasma‑apheresis patent. The Owner argues the petitioner’s inconsistent claim‑construction positions and failure to comply with 37 C.F.R. § 42.104(b)(3) warrant denial. The request cites recent Director precedents to support vacatur.
Samsung Electronics Co., Ltd. et al.vsOura Health Oy et al.
Samsung Electronics challenges Oura Health's wearable computing patents via IPR proceedings, asserting that the claims are obvious under 35 U.S.C. §103. The petition relies on multiple combinations of prior art references related to gesture recognition and biosensing.
Intas Pharmaceuticals, Ltd. et al.vsAtossa Therapeutics, Inc.
Intas Pharmaceuticals successfully secured the institution of IPR against Atossa Therapeutics over a drug polymorph patent (11,261,151), challenging claims based on anticipation and obviousness using prior art Liu.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.